Shots:

• The collaboration will bring Oxford’s recombinant adenovirus vaccine- ChAdOx1 nCoV-19 to the patients and will enable AstraZeneca to be responsible for the development and WW manufacturing and distribution of the vaccine
• The alliance will combine Oxford’s expertise in vaccinology and AstraZeneca’s global development- manufacturing and distribution capabilities to combat the pandemic
• ChAdOx1 is based on adenoviral vector technology and has entered P-I clinical study last week to evaluate its safety and efficacy in healthy volunteers aged 18-55yrs.- across five centers in Southern England with its anticipated results in next month and the expected advancement to late-stage studies by the middle of the year

Click here ­to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca